skip to main content
Idioma:
Mostrar Somente
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
104OIMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
104OIMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
Material Type:
Artigo 		Adicionar ao Meu Espaço

104OIMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

Reck, M ; Jotte, R ; Mok, T S K ; Lim, D W-T ; Cappuzzo, F ; Orlandi, F ; Stroyakovskiy, D ; Nogami, N ; Rodríguez-Abreu, D ; Moro-Sibilot, D ; Thomas, C A ; Barlesi, F ; Finley, G ; Nishio, M ; Lee, A ; Shankar, G ; Yu, W ; Socinski, M A

Annals of oncology, 2019-04, Vol.30 (Supplement_2) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
2
1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)
1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)

Meisel, A. ; Mark, M.T. ; Haider, A. ; Holer, L. ; Hayoz, S. ; Gebhard, C. ; Bengs, S. ; Treyer, V. ; Rothschild, S.I. ; Hochmair, M.J. ; Gandara, D.R. ; Cappuzzo, F. ; Reck, M. ; Stenner-Liewen, F. ; von Moos, R.A.F.

Annals of oncology, 2022-09, Vol.33, p.S1035-S1036 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Material Type:
Artigo 		Adicionar ao Meu Espaço

108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

Garassino, M.C. ; Mazieres, J. ; Reck, M. ; Chouaid, C. ; Bischoff, H. ; Reinmuth, N. ; Cove-Smith, L. ; Mansy, T. ; Cortinovis, D. ; Migliorino, M.R. ; Delmonte, A. ; Garcia Sánchez, J. ; Chara Velarde, L.E. ; Bernabe, R. ; Paz-Ares, L. ; Diaz Perez, I. ; Trunova, N. ; Foroutanpour, K. ; Faivre-Finn, C.

Annals of oncology, 2022-04, Vol.33, p.S81-S82 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315
1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315
Material Type:
Artigo 		Adicionar ao Meu Espaço

1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315

Gröschel, A. ; Passlick, B. ; Stuschke, M. ; Christopoulos, P. ; Reck, M. ; Grah, C. ; Groth, A. ; Hipper, A. ; Chiabudini, M. ; Fleitz, A. ; Jänicke, M. ; Spring, L. ; Christoph, D.C. ; Bernhardt, C. ; Reiser, M. ; Zahn, M-O. ; Sebastian, M. ; Griesinger, F. ; Thomas, M. ; Eberhardt, W.E.E.

Annals of oncology, 2021-09, Vol.32, p.S935-S936 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
5
1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
Material Type:
Artigo 		Adicionar ao Meu Espaço

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

Paz-Ares, L. ; Goto, Y. ; Lim, W.D.T. ; Halmos, B. ; Cho, B.C. ; Dols, M. Cobo ; Gonzalez-Larriba, J.L. ; Zhou, C. ; Demedts, I. ; Atmaca, A. ; Baka, S. ; Mookerjee, B.P. ; Portella, S. ; Zhu, Z. ; Dharan, B. ; Reck, M.

Annals of oncology, 2021-09, Vol.32, p.S953-S954 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
6
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)

Bar, J. ; Kian, W. ; Wolner, M. ; Derijcke, S. ; Girard, N. ; Rottenberg, Y. ; Dudnik, E. ; Metro, G. ; Hochmair, M.J. ; Aboubakar, F. ; Cuppens, K. ; Decoster, L. ; Reck, M. ; Limon, D. ; Blanco, A. Calles ; Astaras, C. ; Häfliger, S. ; Peled, N. ; Addeo, A.

Annals of oncology, 2021-09, Vol.32, p.S961-S962 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
Material Type:
Artigo 		Adicionar ao Meu Espaço

1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome

Nishio, M. ; Paz-Ares, L. ; Reck, M. ; Nakagawa, K. ; Garon, E.B. ; Ceccarelli, M. ; Wijayawardana, S.R. ; Visseren-Grul, C. ; Novello, S.

Annals of oncology, 2021-09, Vol.32, p.S962-S963 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
Material Type:
Artigo 		Adicionar ao Meu Espaço

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

Reck, M. ; Ciuleanu, T.E. ; Pluzanski, A. ; Lee, J.S. ; Bernabe Caro, R. ; Linardou, H. ; Burgers, J. ; Gallardo, C. ; Nishio, M. ; Peters, S. ; Paz-Ares, L.G. ; Hellmann, M.D. ; Borghaei, H. ; Ramalingam, S.S. ; O’Byrne, K. ; Hu, N. ; Bushong, J. ; Eccles, L. ; Grootendorst, D. ; Brahmer, J.R.

Annals of oncology, 2021-12, Vol.32, p.S1430-S1431 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS
1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS
Material Type:
Artigo 		Adicionar ao Meu Espaço

1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS

Socinski, M.A ; Paz-Ares, L ; Luft, A.V ; Szczesna, A ; Ciuleanu, T.E ; Szafranski, W ; Reck, M ; Balint, B ; Park, K ; Schumann, C ; Hirsch, F.R ; Depenbrock, H ; Nanda, S ; Chouaki, N ; Thatcher, N

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv430-iv431 [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
10
1234PA RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER
1234PA RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER
Material Type:
Artigo 		Adicionar ao Meu Espaço

1234PA RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER

Ramalingam, S.S ; Blais, N ; Mazieres, J ; Reck, M ; Jones, C.M ; Juhasz, E ; Urban, L ; Orlov, S ; Barlesi, F ; Kio, E ; Keilholz, U ; Qin, Q ; Qian, J ; Nickner, C ; Dziubinski, J ; McKee, M.D ; Giranda, V.L ; Gorbunova, V.A

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv431-iv431 [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (143)

Data de Publicação 

De até
Refinar
  1. Antes de2010  (4)
  2. 2010Até2012  (18)
  3. 2013Até2015  (21)
  4. 2016Até2019  (64)
  5. Após 2019  (37)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (142)
  2. Japonês  (9)
  3. Russo  (4)
  4. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.